Nuvation Bio (NUVB) has drawn fresh attention after reporting first quarter revenue of US$83.23 million and a profit of US$5.4 million, alongside new FDA and guideline milestones for its oncology drug IBTROZI.

The stock has been volatile, with a 1-day share price return of a 4.56% decline following a strong 7-day share price return of 8.09%. The year-to-date share price return of a 43.94% decline contrasts with a very large 1-year total shareholder return, suggesting momentum has cooled after earlier optimism around IBTROZI approvals, updated clinical data and the earnings swing to profit.

If Nuvation Bio's oncology progress has caught your eye, it may be worth widening the lens to other cancer-focused opportunities. You can use our healthcare AI stock screener as a starting point for ideas 35 healthcare AI stocks.

With IBTROZI gaining global traction and analysts setting higher price targets, Nuvation Bio now trades at a sizeable discount to those views. This raises the question: is this a mispriced oncology growth story, or is the market already looking ahead?

Most Popular Narrative: 53.1% Undervalued

At a last close of $4.81 versus a narrative fair value of $10.25, Nuvation Bio is framed as heavily discounted, with that gap pinned to IBTROZI's potential.

Rapid adoption of IBTROZI in ROS1 positive non small cell lung cancer, combined with a 50 month median duration of response and expanding testing from DNA to RNA based assays, can steadily increase treated prevalence and drive multi year growth in product revenue.

Want to see what justifies this kind of upside gap? Revenue ramps, margin shifts and a long runway in brain tumors sit at the core of this narrative.

Result: Fair Value of $10.25 (UNDERVALUED)

However, the story can change quickly if IBTROZI faces tougher competition in ROS1 lung cancer or if safusidenib timelines slip, which would extend Nuvation Bio's reliance on a single drug.

Next Steps

With investors split between concern and optimism, it makes sense to review the evidence directly and form a clear view quickly. To understand how the key risks and potential rewards compare, see the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use focused screeners to uncover other opportunities that fit your approach.

• Target potential upside across quality businesses by scanning our list of 51 high quality undervalued stocks before others move in.
• Prioritise resilience and sleep easier at night by checking companies in the 71 resilient stocks with low risk scores that score well on overall risk.
• Pinpoint stocks with healthy finances by reviewing the solid balance sheet and fundamentals stocks screener (44 results) and focus on those with stronger balance sheets and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.